AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0062
Drug name and formulations:	Relvar® Ellipta® (fluticasone furoate /vilanterol trifenelate inhalation powder) 92mcg/22mcg and 184mcg/22mcg

Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	No issues
Clinical effectiveness	*Established licensed product*	Both strengths licensed in Asthma, equivalent to established products.
Strength of evidence		Moderate
Cost effectiveness or resource impact	*£*	Currently lowest acquisition cost ICS/LABA dry powder combination.
Place of therapy relative to available treatments	*1/2nd tier*	In line with current ICS/LABA options on formulary; treatment pathway outlined in Asthma guidelines. Offers a once daily dosage regime.
National guidance and priorities	*NICE, MTRAC*	ICS/LABA combination inhalers are included in the BTS/SIGN guidelines last updated in 2016 and support the step-wise approach to the management of asthma. NICE guidance on management of asthma is expected at the end of October 2017.
Local health priorities	*CCG views*	CCGs supportive.
Equity of access	*Equality assessment*	N/A
Stakeholder views	*Define wider groups to be engaged*	N/A
Implementation requirements	*Requires, RICAD ESCA etc.*	Minor amendment to the Asthma Guidelines to reflect the formulary status of Relvar® Ellipta®

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	Green for use in Asthma.
Implementation requirements:	Amend Asthma guidelines to reflect approved formulary status of Relvar® Ellipta®
Implementation monitoring:	